Browse the evidence

Exercise counseling was documented more frequently among patients with durable weight loss after the last GLP-1RA prescription than among those with weight regain (26.2% vs. 14.7%; P = .04).

Incorporating exercise counseling may enhance weight maintenance outcomes for patients after GLP-1RA therapy.

Preliminary dose-dependent weight reductions were observed with KN069.

KN069 may help in achieving weight loss in this demographic.

KN069 led to significant metabolic improvements including lower fasting glucose and triglycerides.

KN069 may improve metabolic health markers in this population.

GLP-1-Rezeptoragonisten, insbesondere Semaglutid, können kardiovaskuläre Ereignisse verhindern.

Semaglutid kann zur Prävention von Herz-Kreislauf-Erkrankungen bei übergewichtigen Patienten eingesetzt werden.

GLP-1 RAs demonstrate multisystemic benefits including cardiovascular risk reduction and improved renal outcomes.

Incorporating GLP-1 RAs in treatment plans may enhance overall patient health beyond weight loss.

Surgeons should recognize GLP-1 RAs as complementary tools within multidisciplinary obesity and metabolic care pathways.

Surgeons should integrate GLP-1 RAs into their treatment strategies for obesity management.

GLP-1 receptor agonist medications have the potential to promote marked weight loss.

Practitioners should consider GLP-1 receptor agonists as a potential option for promoting weight loss.

Obesity should be framed as a chronic, multifactorial disease requiring comprehensive management strategies.

A multidisciplinary approach is essential for effective obesity management.

Emerging agents now include multi-agonists, amylin-based therapies, novel oral compounds, and combination strategies designed to improve not only the magnitude of weight loss, but also its quality, durability, and metabolic consequences.

Practitioners should be aware of new multi-agonist and combination therapies that may offer enhanced benefits for weight loss and metabolic health.

Current data indicate a rapid shift from single-pathway interventions toward multimodal therapeutic strategies in obesity and type 2 diabetes.

Practitioners should consider multimodal approaches as the future direction for treating obesity and type 2 diabetes.

64.8% of patients with obstructive sleep apnea (OSA) presenting to a sleep surgery clinic met FDA-approved criteria for GLP-1 receptor agonist (RA) use.

Practitioners should consider that a significant portion of OSA patients may be eligible for GLP-1 RA treatment.

GLP-1 RA use was associated with significantly lower rates of re-tear (RR = 0.699, p < 0.001).

Practitioners may consider GLP-1 RAs as beneficial for reducing re-tear rates in rotator cuff repair patients.

The DRL agent achieved a prediction accuracy of optimal doses of 92%, exceeding traditional models by 15%.

The DRL agent can provide more accurate dosing recommendations compared to traditional methods.

Plant-based protein has differences compared to animal protein that limit its anabolic capacity.

Practitioners should consider the source of protein when advising on muscle maintenance for elderly or vegetarian individuals.

Intermittent exogenous ketosis (IEK) may increase endurance through glycogen sparing.

Practitioners may consider IEK as a strategy to enhance endurance in athletes.

Acute and chronic post-exercise ketosis may stimulate recovery from training.

Practitioners might use ketosis strategies to aid recovery in athletes.

In patients with type 2 diabetes, retatrutide achieved an absolute HbA1c reduction of 2.02%, with 27% of participants reaching normoglycemia.

Retatrutide may improve glycemic control in patients with type 2 diabetes.

Retatrutide achieves an 82.4% relative reduction in hepatic fat and normalizes liver fat in 86% of patients.

Retatrutide may be beneficial for patients with fatty liver disease.

Total thigh muscle volume decreased by 1.7% after 2 days and 5.5% after 7 days of disuse (P<0.001).

Practitioners should be aware that even short periods of disuse can lead to significant muscle loss.

Myofibrillar protein synthesis rates were 36% lower in the immobilized leg compared to the control leg over one week (P<0.001).

Reduced protein synthesis during disuse highlights the importance of maintaining activity to support muscle health.

Tirzepatide treatment preserved lean mass and muscle function after 4 months.

Tirzepatide may help maintain muscle mass and function during weight loss in obese patients.

Whey and soy proteins can be part of a resistance training regimen, but findings should be interpreted with caution due to small sample size.

Practitioners should consider the potential benefits of protein supplementation while being aware of the limitations of the current evidence.

Nocturnal heart rate variability (HRV) increased from PRE (60 ± 14 ms) to END (69 ± 19 ms) and was strongly associated with the change in fat mass (r= 0.90, p<0.01).

Practitioners may consider monitoring HRV as an indicator of stress adaptation during weight loss in athletes.

Energy availability decreased from 38 ± 3 kcal/kg/FFM to 18 ± 4 kcal/kg/FFM while energy expenditure increased from 24 ± 4 to 44 ± 15 met/h/week from PRE to END.

Practitioners should be aware of the significant changes in energy availability and expenditure during competition preparation.